Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

27.83 +0.67 (+2.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Earnings Scheduled For November 6, 2025
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP... 
Via StockStory
Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst... 
Via StockStory
Topics Artificial Intelligence Economy Government
The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts
 
Via Benzinga
Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
2 Reasons AMPH is Risky and 1 Stock to Buy Instead
Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period. 
Via StockStory
Topics Economy Government Stocks
Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews
 
Via Benzinga
Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
3 Value Stocks with Warning Signs
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Investor's Opportunity
Amphastar Pharmaceuticals appears undervalued with a low P/E ratio, strong profitability, and solid financial health, fitting value investing criteria. 
Via Chartmill
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
3 Small-Cap Stocks That Concern Us
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case
Amphastar Pharmaceuticals (AMPH) is a value stock with strong profitability, a low P/E ratio, and solid financial health, trading below intrinsic value. 
Via Chartmill
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Stock with Strong Fundamentals and Undervalued Potential
Amphastar Pharmaceuticals (AMPH) offers strong value potential with low P/E ratios, high profitability, and stable finances, making it a solid pick for value investors seeking undervalued stocks. 
Via Chartmill
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch. 
Via Benzinga
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit... 
Via StockStory
Amphastar (AMPH) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Supply Chain
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Supply Chain
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.